Novalgen is a clinical-stage company, revolutionizing the immunology landscape with its innovative autoregulation technology. Our focus is on the next generation of multi-specific antibodies to generate transformative outcomes in autoimmune, oncological, and other immunological disorders.

To create and capture the value of our pipeline we have built a strong, vibrant network between academia and various strategic partners, enabling us to leverage their strengths and capabilities, alongside our own, to progress our pipeline safely and expediently through the clinic.